AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00696800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa
Description: On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection of 150 μg (0.5 mL) Corifollitropin Alfa was administered in the abdominal wall.
Study NCT00696800 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RecFSH / Follitropin beta (Days 1 to 7)
Description: Daily SC injections with 200 IU fixed dose recFSH were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
Study NCT00696800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Corifollitropin alfa
Description: Pre-filled syringe containing an identical solution when compared to Corifollitropin Alfa. On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection was administered in the abdominal wall.
Study NCT00696800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo RecFSH / follitropin beta
Description: Identical ready-for-use solution, but without the active ingedient, supplied in cartridges for SC injection with the Follistim Pen. Daily SC injections were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
Study NCT00696800 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RecFSH / Follitropin beta (Days 8 to hCG)
Description: From Stimulation Day 8 onwards a daily SC dose of 200 IU recFSH was administered up to and including the Day of hCG.
Study NCT00696800 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RecFSH / Follitropin beta (Days 8 to hCG)
Description: From Stimulation Day 8 onwards a daily SC dose of 200 IU recFSH was administered up to and including the Day of hCG.
Study NCT00696800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganirelix
Description: On Stimulation Day 5 a daily SC injection of 0.25 mg was started, which continued up to and including the day of hCG
Study NCT00696800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ganirelix
Description: On Stimulation Day 5 a daily SC injection of 0.25 mg was started, which continued up to and including the day of hCG
Study NCT02290535 — intervention group
Intervention type: PROCEDURE
Intervention: probands
Description: Probands will receive the same treatment as patients, but without bronchospasmolysis.
Study NCT02928406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 milligrams (mg) will be administered by intravenous (IV) infusion Q3W.
Study NCT01515982 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: The training exercise intensity is established at 60% of VO2máx. This intensity was determined using exercise prescription guidelines established by the American College of Sports Medicine (ACSM). Each aerobic session began with a 10-minute warm-up period (40%VO2máx), followed by 20 minutes of continuous treadmill walking at an intensity established by 60% of VO2máx. The exercise session will be concluded with a 5 minutes of cool down. Heart hate (Polar® Sport Tester, Finland) and perceived exertion (Borg Scale) will be monitored and recorded at each five minutes during each exercise session by physical education instructors.
Study NCT01515982 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Group
Description: All participants were asked not to commence any new exercise regimen.
Study NCT02902016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GED
Description: Four duodenal biopsies will be collected. Two biopsies will stimulated with GED (PPARgamma modulator) ex vivo during 6 hours. Two biopsies will be unstimulated (control).
Study NCT01811849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin LISPRO
Study NCT01811849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin LISPRO
Study NCT03997786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tildrakizumab
Description: (Weeks 16 to 52)
Study NCT03997786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tildrakizumab
Description: at every 12 weeks in open label fashion till 5 years (240 weeks).
Study NCT03997786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tildrakizumab
Description: (Weeks 0 to 16)
Study NCT03997786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: (Weeks 0 to 16)
Study NCT03997786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: (Weeks 16 to 52)
Study NCT02979691 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SIB-IMRT
Study NCT02979691 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SIB-IMRT
Study NCT02979691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Study NCT02657005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TK216
Description: Inhibitor of protein-protein interactions of EWS-FLI1 fusion protein
Study NCT01676129 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nocipoint Therapy
Study NCT01676129 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Study NCT01845116 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Omegaven®
Description: 10% Omegaven® initiated at a starting dose of 0.5g/kg/day for two days and then advancing to the goal dose of 1g/kg/day, IV (in the vein) until the patient no longer requires parenteral nutrition or until participation in the study is terminated.
Study NCT02833207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug Trial 1 (EDD)
Description: Drugs that increase blood flow and test EDD are: ACh, ISO, BK, ATP. Remaining drugs used to test mechanisms of EDD: L-NMMA, ketorolac, and BaCl2.~Details under study description.
Study NCT02833207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug Trial 2 (ROV)
Description: Tools used to increase blood flow: muscle contractions and ATP. Remaining drugs used to test mechanisms of ROV: L-NMMA, ketorolac, and BaCl2.~Details under study description.
Study NCT00136890 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET Imaging
Description: Patients randomized to PET staging will undergo FDG-PET or PET-CT as well as some form of cranial imaging (CT or MRI)
Study NCT00925756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Maraviroc will be given dose-adjusted to background HIV treatment (150 mg, 300 mg, or 600 mg twice daily)
Study NCT02151175 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LIFUP
Study NCT00696800 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hCG
Description: When 3 follicles >= 17 mm were observed by USS, a single dose of 10,000 IU/USP hCG was administered; or, for those at risk for Ovarian Hyperstimulation Syndrome (OHSS), a lower dose of 5,000 IU/USP
Study NCT00696800 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: hCG
Description: When 3 follicles >= 17 mm were observed by USS, a single dose of 10,000 IU/USP hCG was administered; or, for those at risk for Ovarian Hyperstimulation Syndrome (OHSS), a lower dose of 5,000 IU/USP
Study NCT00696800 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: On the day of OPU, luteal phase support was started by administering micronized progesterone of at least 600 mg/day vaginally, or at least 50 mg/day intramuscular (IM), which continued for at least 6 weeks, or up to menses.
Study NCT00696800 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: On the day of OPU, luteal phase support was started by administering micronized progesterone of at least 600 mg/day vaginally, or at least 50 mg/day intramuscular (IM), which continued for at least 6 weeks, or up to menses.
Study NCT01530360 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cerebral oximeter
Description: INVOS 5100c + SAFB-SM SOMASENSOR NONIN EQUANOX 7600 + sensor model 8000CA
Study NCT02343679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceritinib
Description: Ceritinib will be administered to ALK + hematologic malignancies orally at the 750mg/day dose that has been calculated as the maximum tolerated dose in prior phase I trials in lung cancer patients. Intra patient dose reductions will be allowed for toxicities. Subjects with stable disease or better will be allowed to continue study drug until disease progression or until intolerable adverse events or patient or physician choice.
Study NCT01696695 — intervention group
Intervention type: DRUG
Intervention: Capecitabine
Description: First line capecitabine based oral tablet treatment in line with the effective Summary of Product Characteristics
Study NCT01696695 — intervention group
Intervention type: DRUG
Intervention: Chemotherapy
Description: First line chemotherapy according to effective official Summary of Product Characteristics. The study protocol does not specify any particular therapy.
Study NCT03604484 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tricuspid annuloplasty
Description: Tricuspid annuloplasty
Study NCT03204578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB (Midazolam OD formulation/Dormicum)
Description: Oral disintegrating formulation (Midazolam OD Formulation). The Midazolam OD Formulation was developed by Kyukyu Pharmaceutical Co., Ltd
Study NCT03204578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BA (Dormicum/Midazolam OD formulation)
Description: Oral disintegrating film (Midazolam OD Formulation). The Midazolam OD Formulation was developed by Kyukyu Pharmaceutical Co., Ltd
Study NCT03317340 — intervention group
Intervention type: OTHER
Intervention: Background Sounds
Description: Background music or sound of running water
Study NCT00509444 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational materials
Study NCT00509444 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: educational materials, plus patient navigation
Study NCT01521546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eplerenone
Description: 25mg tablet, once daily by mouth for 12 months
Study NCT01521546 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one tablet by mouth daily for 12 months
Study NCT03875404 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Functional MRI
Description: A special type of MRI measuring the metabolic changes that occur within the brain. It may be used to examine the brain's anatomy and determine which parts of the brain are handling critical functions. It helps identify important language and movement control areas in the brain.
Study NCT01685944 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Live Pediococcus pentosaceus LP28
Study NCT01685944 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Heat-killed Pediococcus pentosaceus LP28
Study NCT01685944 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01205204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: GROUP BF25 (CONTROL) In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 25 mcg of fentanyl, intrathecally.
Study NCT01205204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5%with15 mcg of clonidine, intrathecally.
Study NCT01205204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 30 mcg of clonidine, intrathecally.
Study NCT01205204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clonidine
Description: In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 60 mcg of clonidine, intrathecally.
Study NCT01024075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 4cc of Dexamethasone and 4cc of Saline mixed with Sinufoam
Study NCT04591470 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Mar test
Description: Study of antisperm antibodies
Study NCT00506077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0249
Description: MK0249 10mg (2 x 5 mg) tablet daily (qd) for 28 days.
Study NCT00506077 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo (unspecified)
Description: MK0249 10mg (2 x 5 mg) Pbo tablet qd for a 28 day treatment period.
Study NCT02275689 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic acromioplasty
Description: Surgical intervention With arthroscopic acromion resection
Study NCT02275689 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microtenotomy
Description: Arthroscopic radiofrequency microtenotomy of rotator cuff tendon
Study NCT01234012 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMF-001
Description: subcutaneous injection of fixed dose IMF-001 (100 or 200 mcg) every 2 weeks.
Study NCT02831075 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adipose-derived stem cell
Description: stem cell acquisition, processing and reinfection, to evaluate the efficacy of adipose-derived stem cell.
Study NCT02831075 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: saline
Study NCT04645459 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low phosphorus meals
Description: All subjects followed their usual diets but took one tablet of calcium carbonate as phosphate binder per meal for the first week washout diet. After washout diet, subjects were assign to control or study group randomly and entered to the study period for one week. The diets of the study group were low phosphorus ( LP group), but the dietary phosphorous levels of the control group were not modified. During the study period, all subjects including LP group and control group still kept their usually accustomed behavior about regular breakfast and also took one tablet of calcium carbonate as phosphate binder with every breakfast meal. The LP group and control group replaced daily lunch and dinner with low phosphorus and standard meals respectively and should not take any phosphate binder during the study period for one week.
Study NCT04645459 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control meals
Description: All subjects followed their usual diets but took one tablet of calcium carbonate as phosphate binder per meal for the first week washout diet. After washout diet, subjects were assign to control or study group randomly and entered to the study period for one week. The diets of the study group were low phosphorus ( LP group), but the dietary phosphorous levels of the control group were not modified. During the study period, all subjects including LP group and control group still kept their usually accustomed behavior about regular breakfast and also took one tablet of calcium carbonate as phosphate binder with every breakfast meal. The LP group and control group replaced daily lunch and dinner with low phosphorus and standard meals respectively and should not take any phosphate binder during the study period for one week.
Study NCT03698669 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treating Opioid Patients' Pain and Sadness (TOPPS)
Description: TOPPS involves an initial face-to-face meeting followed by regular phone meetings. In preliminary research, patients found this format to be convenient. The initial meeting includes the patient, the BHS and the PCP; the PCP then regularly receives treatment notes from the BHS. Also, the PCP, who has a longitudinal relationship with the patient, is encouraged to further reinforce TOPPS goals. After each TOPPS session, the BHS also mails a copy of the clinical note to the patient. Additionally, each participant is provided with a workbook that reviews the key elements of each treatment session and provides exercises for at-home practice of skills.
Study NCT03698669 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education (HE)
Description: After an initial, brief, joint, in-person meeting with the BHS and primary care physician (PCP), patients have a session that discusses nutrition. For the next 5 telephone sessions, they choose from a menu of topics, including: a second session on nutrition; germs, colds and the flu; preventing cancer; diabetes; protecting your heart; getting a good night's sleep; complementary and alternative medicine; caffeine, or physical activity. This control condition was accepted by our participants in preliminary studies; it does not directly target functional impairment, and participants do not set tailored goals relating to their own values. The BHS will communicate with the PCP only if a participant shows signs of clinical deterioration.
Study NCT01024075 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 8cc of Saline mixed with Sinufoam
Study NCT01556334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin 1g po
Study NCT01556334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythromycin
Description: Erythromycin IV then PO
Study NCT04439253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Given PO
Study NCT03433339 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active transcutaneous spinal direct current stimulation
Description: Active anode electrodes placed at Thoracic 10 level, Cathode electrode placed on right shoulder.
Study NCT03433339 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcutaneous spinal direct current stimulation
Description: Sham anode electrodes placed at Thoracic 10 level, Cathode electrode placed on right shoulder.
Study NCT00837369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: 400ug IV bolus injection, single dosage
Study NCT02790931 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: Patients will receive a physical therapy intervention in groups twice/wk, and using a software twice/ wk for 3 months, for foot and ankle strengthening, stretching and functional training. They must continue to exercise at home twice a week with the software supervision for one year.
Study NCT03789214 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo Sleep Medication
Study NCT03789214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose Suvorexant
Description: Low Dose Suvorexant
Study NCT03789214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High Dose Suvorexant
Description: High Dose Suvorexant
Study NCT00479193 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: bacitracin/xeroform
Description: single layer, change every 3 days
Study NCT00479193 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Polymem
Description: single layer of Polymen, change every 3 days
Study NCT01232595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFF571
Study NCT01232595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin (POC)
Study NCT01708161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Description: BYL719 is a small molecule inhibiting PI3-Kinase.
Study NCT01708161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 479
Description: AMG 479 is a monoclonal antibody directed against IGF1-R.
Study NCT04289142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Hydrochloride Group
Description: Dexmedetomidine will be initiated prior to transfer to the CVICU with loading dose of 1.2 ug/kg over approximately 20 minutes. This will be followed by an infusion at 0.3 ug/kg/h in CVICU for up to 12 hours from the time DEX infusion started or until the patient is ready for discharge from the CVICU (whichever is earlier). Any additional sedatives necessary at the discretion of ICU.
Study NCT02581787 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fresolimumab
Description: Given IV
Study NCT02581787 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SABR
Study NCT00765557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MiraLAX
Description: Every subject will be given one bottle of the polyethylene glycol/placebo, divided into daily doses and depending on the patient's age, will be instructed to take 8.5 grams or 17 grams of the medication dispensed in daily dose vials to be mixed with water or juice. They will take the medication once a day for one month.
Study NCT00765557 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MiraLAX
Description: Every subject will be given one bottle of the polyethylene glycol/placebo, divided into daily doses and depending on the patient's age, will be instructed to take 8.5 grams or 17 grams of the medication dispensed in daily dose vials to be mixed with water or juice. They will take the medication once a day for one month.
Study NCT00765557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: Every subject will be given one bottle of the polyethylene glycol/placebo, divided into daily doses and depending on the patient's age, will be instructed to take 8.5 grams or 17 grams of the medication dispensed in daily dose vials to be mixed with water or juice. They will take the medication once a day for one month.